RNA Pol II Inhibitor-Bacteria is under clinical development by Hamlet Pharma and currently in Phase I for Inflammation.

Obudanersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Angelman Syndrome.

Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock ...

The new collaboration and nonexclusive license agreement between Epitopea and Genevant Sciences will see the Cambridge ...

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in ...

When children receive their second measles-mumps-rubella vaccine, around the time they start kindergarten, they gain protection against all three viruses for all or most of their lives.

A new test can differentiate between various types of asthma via a nasal swab. Researchers hope it can eventually help match ...

Background and objective Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic ...

When children receive their second measles-mumps-rubella vaccine, around the time they start kindergarten, they gain ...

A new study conducted at the Scojen Institute for Synthetic Biology at Reichman University's Dina Recanati School of Medicine ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...